| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Sterility | 0.22 μm Filtered |
| Clone | Amatuximab |
| Source/Isotype | Human IgG1 kappa |
| Application | Flow Cytometry |
| Specificity | Detects MSLN |
| Gene | MSLN |
| Other Names | MPF, SMRP |
| Gene ID | 10232 (human) |
| Background | MSLN is over expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. MSLN is a tumor differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. Since mesothelin is overexpressed in several cancers and is immunogenic, the protein could be exploited as tumor marker or as the antigenic target of a therapeutic cancer vaccine. |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Sterility | 0.22 μm Filtered |
| Clone | Amatuximab |
| Source/Isotype | Human IgG1 kappa |
| Application | Flow Cytometry |
| Specificity | Detects MSLN |
| Gene | MSLN |
| Other Names | MPF, SMRP |
| Gene ID | 10232 (human) |
| Background | MSLN is over expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. MSLN is a tumor differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. Since mesothelin is overexpressed in several cancers and is immunogenic, the protein could be exploited as tumor marker or as the antigenic target of a therapeutic cancer vaccine. |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
